252 related articles for article (PubMed ID: 19852531)
1. Lanthanum carbonate: a review of its use in lowering serum phosphate in patients with end-stage renal disease.
Curran MP; Robinson DM
Drugs; 2009 Nov; 69(16):2329-49. PubMed ID: 19852531
[TBL] [Abstract][Full Text] [Related]
2. A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.
Prajapati VA; Galani VJ; Shah PR
Saudi J Kidney Dis Transpl; 2014 May; 25(3):530-8. PubMed ID: 24821148
[TBL] [Abstract][Full Text] [Related]
3. Effect of lanthanum carbonate on phosphate control in continuous ambulatory peritoneal dialysis patients in Korea: a randomized prospective study.
Lee YK; Choi HY; Shin SK; Lee HY
Clin Nephrol; 2013 Feb; 79(2):136-42. PubMed ID: 23211335
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of continuous oral administration of lanthanum carbonate over 24 months.
Ishizu T; Hong Z; Matsunaga T; Kaneko Y; Taru Y
Ther Apher Dial; 2013 Apr; 17 Suppl 1():22-8. PubMed ID: 23586509
[TBL] [Abstract][Full Text] [Related]
5. A meta-analysis of phosphate binders lanthanum carbonate versus sevelamer hydrochloride in patients with end-stage renal disease undergoing hemodialysis.
Zhou T; Li H; Xie W; Lin Z
Afr Health Sci; 2018 Sep; 18(3):689-696. PubMed ID: 30603002
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study.
Hutchison AJ; Maes B; Vanwalleghem J; Asmus G; Mohamed E; Schmieder R; Backs W; Jamar R; Vosskühler A
Nephron Clin Pract; 2006; 102(2):c61-71. PubMed ID: 16224198
[TBL] [Abstract][Full Text] [Related]
7. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
Sprague SM
Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
[TBL] [Abstract][Full Text] [Related]
8. Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease.
Chiang SS; Chen JB; Yang WC
Clin Nephrol; 2005 Jun; 63(6):461-70. PubMed ID: 15960148
[TBL] [Abstract][Full Text] [Related]
9. Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis.
Goldsmith DR; Scott LJ; Cvetković RS; Plosker GL
Drugs; 2008; 68(1):85-104. PubMed ID: 18081374
[TBL] [Abstract][Full Text] [Related]
10. Safety of new phosphate binders for chronic renal failure.
Loghman-Adham M
Drug Saf; 2003; 26(15):1093-115. PubMed ID: 14640773
[TBL] [Abstract][Full Text] [Related]
11. Study of prolonged administration of lanthanum carbonate in dialysis patients.
Gotoh J; Kukita K; Tsuchihashi S; Hattori M; Iida J; Horie T; Onodera K; Furui H; Tamaki T; Meguro J; Yonekawa M; Kawamura A
Ther Apher Dial; 2013 Apr; 17 Suppl 1():9-14. PubMed ID: 23586507
[TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia.
Joy MS; Finn WF;
Am J Kidney Dis; 2003 Jul; 42(1):96-107. PubMed ID: 12830461
[TBL] [Abstract][Full Text] [Related]
13. Hyperphosphatemia in dialysis patients: the therapeutic role of lanthanum carbonate.
Cozzolino M; Brancaccio D
Int J Artif Organs; 2007 Apr; 30(4):293-300. PubMed ID: 17520565
[TBL] [Abstract][Full Text] [Related]
14. Lanthanum carbonate.
Swainston Harrison T; Scott LJ
Drugs; 2004; 64(9):985-96; discussion 997-8. PubMed ID: 15101790
[TBL] [Abstract][Full Text] [Related]
15. Lanthanum carbonate for hyperphosphatemia in patients on peritoneal dialysis.
Ohno M; Ohashi H; Oda H; Yokoyama H; Okada M; Nagaya M; Izumi K; Ito H; Katoh S
Perit Dial Int; 2013; 33(3):297-303. PubMed ID: 23209037
[TBL] [Abstract][Full Text] [Related]
16. Pharmacology of the phosphate binder, lanthanum carbonate.
Damment SJ
Ren Fail; 2011; 33(2):217-24. PubMed ID: 21332344
[TBL] [Abstract][Full Text] [Related]
17. Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis.
Shigematsu T;
Ther Apher Dial; 2008 Feb; 12(1):55-61. PubMed ID: 18257813
[TBL] [Abstract][Full Text] [Related]
18. Three-year follow-up of lanthanum carbonate therapy in hemodialysis patients.
Takeuchi K; Matsuda E; Sekino M; Hasegawa Y; Kamo Y; Kikuchi N; Sekino H
Ther Apher Dial; 2013 Apr; 17 Suppl 1():15-21. PubMed ID: 23586508
[TBL] [Abstract][Full Text] [Related]
19. [Phosphate binder up to date].
Shigematsu T; Sakaguchi T; Orita H
Clin Calcium; 2007 May; 17(5):772-8. PubMed ID: 17471009
[TBL] [Abstract][Full Text] [Related]
20. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients.
D'Haese PC; Spasovski GB; Sikole A; Hutchison A; Freemont TJ; Sulkova S; Swanepoel C; Pejanovic S; Djukanovic L; Balducci A; Coen G; Sulowicz W; Ferreira A; Torres A; Curic S; Popovic M; Dimkovic N; De Broe ME
Kidney Int Suppl; 2003 Jun; (85):S73-8. PubMed ID: 12753271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]